Citadel Advisors
JANX icon

Citadel Advisors’s Janux Therapeutics JANX Stock Holding History

Citadel Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$395K Sell
25,700
-17,800
-41% -$258K ﹤0.01% 10467
2026
Q1 		$605K Sell
43,500
-40,300
-48% -$553K ﹤0.01% 8834
2025
Q4 		$1.16M Buy
83,800
+69,300
+478% +$1.63M ﹤0.01% 7073
2025
Q3 		$354K Sell
14,500
-3,900
-21% -$95K ﹤0.01% 9963
2025
Q2 		$425K Buy
18,400
+1,700
+10% +$44.8K ﹤0.01% 9013
2025
Q1 		$451K Sell
16,700
-19,300
-54% -$728K ﹤0.01% 8701
2024
Q4 		$1.93M Sell
36,000
-15,100
-30% -$799K ﹤0.01% 5712
2024
Q3 		$2.32M Buy
51,100
+21,700
+74% +$944K ﹤0.01% 5253
2024
Q2 		$1.23M Sell
29,400
-22,600
-43% -$1.06M ﹤0.01% 6194
2024
Q1 		$1.96M Buy
52,000
+51,300
+7,329% +$1.12M ﹤0.01% 5564
2023
Q4 		$7.51K Buy
700
+300
+75% +$2.59K ﹤0.01% 13284
2023
Q3 		$4.03K Sell
400
-1,000
-71% -$11.5K ﹤0.01% 13523
2023
Q2 		$16.6K Sell
1,400
-700
-33% -$9.36K ﹤0.01% 12891
2023
Q1 		$25.4K Buy
2,100
+500
+31% +$8.32K ﹤0.01% 12873
2022
Q4 		$21.1K Buy
+1,600
New +$23.4K ﹤0.01% 13109

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Citadel Advisors's JANX Position: Q2 2026 in Review

Citadel Advisors increased its Janux Therapeutics (JANX) stake by 241% in Q2 2026, buying an estimated $12.3M and bringing the position to 1,200,737 shares worth $18.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2691.

Citadel Advisors first reported a position in JANX in Q2 2021 and has held it in 21 quarters since. The position peaked at $88.5M in Q1 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Citadel Advisors held 1,200,737 shares of Janux Therapeutics worth $18.4M as of Q2 2026.
  • Citadel Advisors bought 848,560 Janux Therapeutics shares in Q2 2026, an estimated $12.3M.
  • Janux Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2691 holding.
  • Citadel Advisors first reported a position in Janux Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Citadel Advisors's Janux Therapeutics position peaked at $88.5M in Q1 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.